Investigational drug · Phase 2
RTP-026
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for ST Elevation Myocardial Infarction.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "RTP-026"
First trial start
2024
Jul 16, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RTP-026", any sponsor or status.
Conditions studied
As listed on its trial records.
- ST Elevation Myocardial Infarction
Approved drugs for the same conditions: Coronary artery disease and heart attack · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "RTP-026" as an intervention, largest first.
ResoTher PharmaIndustry
NCT06465303 · 66 participants · Start Jul 16, 2024 · Primary completion Jul 2, 2026
Drug: RTP-026; Placebo · For: ST Elevation Myocardial Infarction
Sites: Copenhagen, Denmark
Newest research
PubMed records naming it or its code names, newest first.
- Research Progress of Annexin A1 and Its Derived Peptides in the Diagnosis and Treatment of Circulatory Diseases.
Dai Q, Zheng J, Fu M, et al. · Immun Inflamm Dis 2025
- Pro-resolving lipid mediators and therapeutic innovations in resolution of inflammation.
Peh HY, Chen J · Pharmacol Ther 2025
- The Annexin-A1 mimetic RTP-026 promotes acute cardioprotection through modulation of immune cell activation.
Chen J, Oggero S, Cecconello C, et al. · Pharmacol Res 2023
Also in development for ST Elevation Myocardial Infarction
- Allogeneic umbilical cord mesenchymal stem cellsPhase 23 trials
Ever Supreme Bio Technology Co., Ltd. · COVID-19 Infection, Multiple Sclerosis, ST Elevation Myocardial Infarction
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.